Loading
Loading
Metabolic & Body Composition · 10mg
Janoshik-tested · 10 vials per kit
Adipotide is a synthetic chimeric peptide studied in preclinical research for its proapoptotic targeting of white adipose tissue vasculature. Research has examined its potential to selectively bind prohibitin on blood vessels supplying adipose tissue, induce apoptosis in vascular endothelial cells within fat deposits, and reduce adipose tissue mass. Studies in primate models have observed significant reductions in visceral fat and BMI.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Adipotide
CKGGRAKDC-GG-D(KLAKLAK)₂
Adipotide is a bimodal targeting peptide comprising two functional domains: CKGGRAKDC (a targeting sequence that binds prohibitin on the luminal surface of white adipose tissue vasculature) and D(KLAKLAK)2 (a proapoptotic, mitochondria-disrupting sequence). Developed by Pasqualini and Arap at MD Anderson Cancer Center using in vivo phage display to identify peptides that home specifically to adipose tissue blood vessels.
The CKGGRAKDC targeting domain binds prohibitin expressed specifically on the endothelial lining of blood vessels supplying white adipose tissue — a receptor not found on vasculature of other tissues. Upon internalisation, the D(KLAKLAK)2 domain disrupts mitochondrial membranes in the targeted endothelial cells, triggering apoptosis. Destruction of the adipose vasculature deprives local adipocytes of their blood supply, leading to adipocyte apoptosis and tissue reduction without systemic toxicity.
Obese non-human primate studies showed dose-dependent reduction in body fat (up to 11% weight loss in 28 days) proportional to initial adiposity, without apparent effects on lean mass or vital organs. The mechanism differs fundamentally from all other metabolic interventions, as it physically removes adipose vasculature rather than suppressing appetite or altering energy metabolism.
Key References
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
